AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05877560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal-Transcranial Direct Current Stimulation
Description: Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.
Study NCT05877560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office-Based Vergence/Accommodative Therapy
Description: Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
Study NCT05877560 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Office-Based Vergence/Accommodative Therapy
Description: Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.
Study NCT05877560 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.
Study NCT05015478 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Rhythmic Lighting Intervention
Description: 40 hertz (Hz) rhythmic lighting (RL) for a duration of 1 hour. The flicker frequency of the 40 Hz RL will be 40 Hz and the stimulation will be a square wave with a 50 % duty cycle (i.e., 12.5 milliseconds light- on and 12.5 milliseconds light-off). The RL will provide a 30 lux of red light on a vertical plane at the eye level.
Study NCT05015478 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Rhythmic Lighting Intervention
Description: Placebo rhythmic light (RL) for a duration of 1 hour. In the placebo RL condition, the duty cycle will be delivered at randomly varying frequencies of 20 Hz and 50 Hz, specifically avoiding the frequency of 40 Hz. The placebo RL conditions will provide a 30 lux of red light on a vertical plane at the eye level.
Study NCT05499585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Whole Dairy
Description: 2 1/2 servings of whole dairy per day
Study NCT06584513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific tapering plan for sleep medication, educational and cognitive behavioural therapy elements
Description: The intervention consists of a patient-centred intervention to help patients in deprescribing BSHs and better managing their sleep problems. The material used consists of training modules, brochures, and self-monitoring tools. There are materials for physicians and for patients.
Study NCT05873062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUT00201
Description: Single oral dose
Study NCT05873062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study NCT05199740 — intervention group
Intervention type: OTHER
Intervention: in vitro analysis
Description: in vitro analysis of mesoangioblasts from mtDNA mutation carriers
Study NCT04960800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific exercises
Description: Specific exercises which aims to contract the recti abdominis combined with functional exercises with the aim to contract all the layers of the anterior abdominal wall. Strengthening dosage will be applied with 3 sets, containing between 8 and 12 repetitions of maximal load.
Study NCT04161066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin with facilitated counseling
Description: open-label pilot study
Study NCT04832087 — intervention group
Intervention type: DRUG
Intervention: Teduglutide
Description: Standard of care Teduglutide dosing
Study NCT06020040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heterograft
Description: Heterograft (Geistlich, Gegreen, Heal-All) will be used to repair bone defect in the esthetic area of the anterior teeth with simultaneous implant placement. According to the bone particle size, it can be divided into large bone particles(1-2mm) and small bone particles(0.25-1mm).
Study NCT04522531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open cinetic chain shoulder exercise on unstabil ground
Description: Open cinetic chain shoulder exercise will be performed on BOSU which provides an unstabil ground. This exercises will be include PNF (flexion-adduction-external rotation pattern), PNF (flexion-abduction-external rotation pattern), scapular plan abduction, external rotation while keeping shoulder in 45 degree abduction. The weight which used during exercise planned according to individuals body weight: 0-59 kg: 3 kg; 60-69 kg: 4 kg; 70-85 kg: 5Kg. Exercises will be carried out in 3 phases consisting of concantric, isometric and eccentric phases. Each phase will be lasted 3 seconds. The time will be checked by using a metronome.
Study NCT05755737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Serotonin antagonists (5-HT3 antagonists) (Carbazole Derivative)
Study NCT05755737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo identical in appearance.
Study NCT05241431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: 10 mg orally once daily in addition to standard medical treatment.
Study NCT05241431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets similar to active treatment.
Study NCT06374771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: 10 mg of Melatonin will be given orally pre and post-operative
Study NCT06374771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 1 gm of Vitamin C will be given orally pre and post-operative
Study NCT05472324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731 injection
Description: TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.
Study NCT05472324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The drug is a placebo Comparator.
Study NCT06505980 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Behavioral Parenting Program
Description: The brief behavioral parenting program is a 6 session, group-based behavioral parent training program. The components include support-building, parenting strategy education, and actively practicing parenting strategies. It is delivered through telehealth.
Study NCT03854188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Use acupuncture therapy in the treatment of chronic pelvic pain.
Study NCT05237297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole
Description: Ilaprazole 10mg
Study NCT05237297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg
Study NCT05237297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclofenac
Description: Aceclofenac 100mg
Study NCT06008678 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RXiBreeze PAP System, Model RXiBreeze 20A
Description: The RXiBreeze PAP System is a prescription-only positive airway pressure (PAP) ventilator used to treat obstructive sleep apnea (OSA). It is a microprocessor-controlled device that provides mechanical ventilation to a subject.
Study NCT05191797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bomedemstat
Description: Given PO
Study NCT05191797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05067283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral dose
Study NCT05067283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion of 200 mg
Study NCT05067283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Per label
Study NCT05067283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Per label
Study NCT05067283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Per label
Study NCT05067283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Per label
Study NCT05067283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Per label
Study NCT05067283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Per label
Study NCT05962125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periodic alveolar recruitment maneuvers
Description: A stepwise increment of tidal volume was used for each ARM.
Study NCT05962125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodic alveolar recruitment maneuvers
Description: A stepwise increment of tidal volume was used for each ARM.
Study NCT05962125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: positive end-expiratory pressure
Description: a PEEP of 6 to 8 cm H2O
Study NCT06414902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArabinoFuranosylGuanine [18F]F-AraG
Description: Given by IV
Study NCT05971381 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RECELL® Autologous Cell Harvesting Device
Description: The RECELL Device is for use at the patient's point-of-care for the safe and rapid preparation of Spray-On SkinTM Cells from a small sample of a patient's own skin.
Study NCT06401577 — intervention group
Intervention type: DEVICE
Intervention: Dexcom Continuous Glucose Monitor (CGM)
Description: Dexcom Continuous Glucose Monitor which measures and records a participant's serum glucose level
Study NCT06362837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education intervention on nutrition, gender equity, WASH, sexual and reproductive health rights
Description: Educational training on nutrition, gender equity, WASH, sexual and reproductive health rights will take place in communities (including schools) for women, men, and adolescents
Study NCT06362837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: school-based iron-folic acid supplement program
Description: The program will help support and promote the school-based programs of weekly iron and folic acid supplementation for adolescent girls, in countries where it is allowed.
Study NCT06362837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health service training on equitable access to nutrition, health, and sexual and reproductive services
Description: Training and support activities to make gender-equitable nutrition, health, and sexual and reproductive services in the health facilities
Study NCT06362837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: bio-fortified crops
Description: The program promotes and distributes bio-fortified crops, including orange-fleshed sweet potatoes, rice, beans, and corn
Study NCT04991025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle. Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
Study NCT04991025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 intravenously on day 1 of a 21 day cycle
Study NCT04991025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of a 21 day cycle.
Study NCT05237297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200mg
Study NCT04991025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants not eligible for cisplatin (per treating physician discretion) may receive carboplatin at AUC = 5 instead of cisplatin.
Study NCT04991025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab
Description: Certolizumab 400mg subq will be administered in clinic within 1 hour before the start of chemotherapy on day 1 of a 21 day cycle.
Study NCT04991025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants with lung adenocarcinoma will receive standard of care neoadjuvant cisplatin 75mg/m2 + pemetrexed 500mg/m2 + nivolumab 360mg intravenously on day 1 of a 21 day cycle Participants with squamous cell lung carcinoma will receive cisplatin 75mg/m2 IV on day 8 of a 21 day cycle + gemcitabine 1000mg/m2 IV days 1 and 8 of 21 day cycle + nivolumab 360mg IV on day 1 of 21 day cycle.
Study NCT06674005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cucurbita pepo L. Flowers Extract
Description: 2 mg twice per day for 1 month
Study NCT06674005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg twice per day for 1 month
Study NCT06674148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qifangfeixian granules
Description: The experimental group was treated with Qifangfixian granules
Study NCT06529757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body cooling
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to whole body skin wetting. Skin wetting will be performed by spraying water onto the whole body throughout the exercise bout.
Study NCT06529757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-cooling
Description: Subjects will exercise for 60 minutes in the indicated environmental condition while being exposed to no cooling modalities.
Study NCT05232942 — intervention group
Intervention type: OTHER
Intervention: Headache calendar completion
Description: The patient will complete an in-paper or electronic calendar, depicting the presence/absence of headache, the median intensity and the need of acute medication.
Study NCT06674148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group was treated with placebo
Study NCT05558644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single arm for all patients
Description: * tumor samples will be taken for RNA sequencing of epithelial tumour cells during surgery.~* blood samples will be taken for Exome Sequencing (WES) at baseline, during surgery and one month post surgery.
Study NCT04767048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral mucosectomy + tonsillectomy
Description: Basic bilateral tongue mucosectomy assisted by robot or laser plus tonsillectomy (unilateral or bilateral at the choice of the investigator)
Study NCT04767048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Description: tonsillectomy (unilateral or bilateral at the choice of the investigator)
Study NCT06679283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement with a chemo-electric device + PRF
Description: The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed followed by application of PRF clots and membrane. Then, the flap will be closed and sutured.
Study NCT06679283 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement with a chemo-electric device alone (control)
Description: The defects will be removed from granulation tissue. Debridement by a chemical-electrical principle will be performed. Then the flap will be closed and sutured.
Study NCT06673901 — intervention group
Intervention type: DEVICE
Intervention: Measurments
Description: Each angle was measured three times, and the mean was calculated to represent the data used for statistical analysis. The assessment position for all measurements was relaxed, comfortable standing position and wearing loose clothing, bare feet, and one foot apart between two feet on a level floor in the same room of the same building, at the same time of day. There was a fixed point in the wall, and the woman was instructed to look at it during the assessment; this point adjusts at the level of her eyes. No specific instructions were provided to the females regarding posture so that measurements during a normal standing position. Data was recorded in a data-collecting sheet.
Study NCT06675344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Neuro Device
Description: The Apollo Neuro wearable device is an Apple Watch-sized wearable device that delivers vibration at set frequencies , termed transcutaneous vibratory stimulation, or TVS. These low volume sound waves feel like a soothing touch to the skin (TVS) and activate touch receptors. Apollo is controlled via smartphone and worn on the wrist or ankle. The Apollo is fitted with an adjustable band, made of a durable neoprene material with polyester overlays. Participants are asked to wear it daily for a minimum time period for 6 weeks. Users can choose from different modes of vibration, with some being energizing, others relaxing.
Study NCT05672121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH631
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Study NCT06675344 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The Apollo Neuro is an Apple Watch-sized wearable device that delivers vibration, termed transcutaneous vibratory stimulation, or TVS. The sham device is identical in appearance to the active intervention, but provides a lower frequency vibration that has no known therapeutic benefit.
Study NCT05490238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Description: Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Study NCT05490238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Description: Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)
Study NCT05379686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GlucaGen
Description: 150 ug glucagon will be administered to the participants before exercise.
Study NCT06161441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Administered intravenously (IV) every 3 weeks (Q3W)
Study NCT06161441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered IV Q3W
Study NCT06161441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered IV Q3W
Study NCT06161441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV Q3W
Study NCT06596135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Open-label daily injections of setmelanotide
Study NCT06689995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio-immune Capsule
Description: Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg
Study NCT06689995 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days
Study NCT06687083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal high frequency oscillatory ventilation mode
Description: Preterm neonates who will be allocated will start nHFOV: (CNO, Medin, Germany). nHFOV will be provided via binasal prongs (Size: small, medium, large; Diameter according to its chart; Medin, Germany).~The initial parameters will be mean airway pressure (MAP) of 6 cm H2O (range 6-10), frequency of 8 Hz (range 8-12) and amplitude will be adjusted until infant's chest showed slight oscillations and amplitude will be 7 (range 7-10).~The fraction of inspired oxygen (FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter.
Study NCT06687083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive pressure ventilation mode
Description: Preterm neonates who will be allocated to this group to the nCPAP will be started on a pressure of 6-8 cm H2O, FiO2) will be adjusted to maintain target oxygen saturation (SpO2) from 92% to 95% by a pulse oximeter
Study NCT04837196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7517
Description: Intravenous (IV)